Arca
Skip to content
Tools
Tools

Serine/threonine-protein kinase AKT

Family in Homo sapiens that 13 drugs act on.

  • Drugs that act on it: 13
  • Approved: 1
  • In phases 1 to 3: 12
  • Sponsors: 9
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on AKT1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 11
  • Other 2

Approved1

  • Capivasertib

Phase 32

  • Ipatasertib
  • Afuresertib

Phase 25

  • Miransertib
  • MK-2206
  • Uprosertib
  • Pifusertib
  • Triciribine phosphate

Phase 15

  • GSK-690693
  • LY-2780301
  • MK-2201
  • TAS0612
  • XL-418

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Laekna Limited18%
  • Prescient Therapeutics, Ltd.18%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 12 of 13 act as: Serine/threonine-protein kinase AKT inhibitor; the rest name their own mechanism.
CapivasertibApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor41
IpatasertibPhase 3RocheSmall moleculeInhibitor21
AfuresertibPhase 3Laekna LimitedSmall moleculeInhibitor1
MiransertibPhase 2Merck & Co. (MSD)Small moleculeInhibitor2
MK-2206Phase 2—Small moleculeInhibitor2
UprosertibPhase 2—Small moleculeInhibitor1
PifusertibPhase 2Taiho OncologySmall moleculeNegative allosteric modulatorSerine/threonine-protein kinase AKT negative allosteric modulator0
Triciribine phosphatePhase 2Prescient Therapeutics, Ltd.Small moleculeInhibitor0
GSK-690693Phase 1GSKSmall moleculeInhibitor0
LY-2780301Phase 1Eli LillyOtherInhibitor0
MK-2201Phase 1—OtherInhibitor0
TAS0612Phase 1Taiho OncologySmall moleculeInhibitor0
XL-418Phase 1ExelixisSmall moleculeInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov.
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingCapivasertibPhase 3Not yet recruitingSWOG Cancer Research NetworkSep 3, 2026
Immunotherapy Plus Capivasertib for Metastatic Bladder CancerCapivasertibPhase 1 / Phase 2Not yet recruitingVA Office of Research and DevelopmentAug 28, 2026
Fast-Her: Fasting Effects on Breast Cancer TreatmentCapivasertibNot applicableRecruitingUniversity of MinnesotaJun 3, 2026
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibCapivasertibPhase 1 / Phase 2Not yet recruitingShanxi Province Cancer HospitalMar 20, 2026
Rash & Diarrhea Prophylaxis With CapivasertibCapivasertibPhase 2RecruitingMaryam LustbergFeb 23, 2026
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentCapivasertibPhase 1RecruitingAstraZenecaJan 15, 2026
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLCapivasertibPhase 1 / Phase 2RecruitingUniversity of ChicagoDec 19, 2025
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsCapivasertibPhase 1 / Phase 2RecruitingAminex Therapeutics, Inc.Dec 17, 2025
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)IpatasertibPhase 2Active, not recruitingNational Cancer Institute (NCI)May 6, 2024
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyIpatasertibPhase 3RecruitingHoffmann-La RocheMay 17, 2023
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialIpatasertibPhase 2RecruitingNational Cancer Institute (NCI)Oct 3, 2022
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialIpatasertibPhase 2Active, not recruitingNational Cancer Institute (NCI)Sep 26, 2022
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersIpatasertibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Sep 14, 2022
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCIpatasertibPhase 2Active, not recruitingQueen Mary University of LondonAug 12, 2022
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)IpatasertibPhase 2RecruitingGerman Cancer Research CenterApr 18, 2022
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian CancerIpatasertibPhase 1Active, not recruitingNational Cancer Institute (NCI)Mar 14, 2022
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)MiransertibPhase 2Active, not recruitingMerck Sharp & Dohme LLCJul 28, 2021
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerAfuresertibPhase 3Active, not recruitingLaekna LimitedApr 20, 2021
MK-7075 (Miransertib) in Proteus SyndromeMiransertibPhase 2Active, not recruitingNational Human Genome Research Institute (NHGRI)Mar 20, 2020
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal MelanomaUprosertibPhase 2Active, not recruitingNational Cancer Institute (NCI)Nov 8, 2013
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerMK-2206Phase 1Active, not recruitingNational Cancer Institute (NCI)Nov 28, 2011
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerMK-2206Phase 2RecruitingQuantumLeap Healthcare CollaborativeJan 5, 2010

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111353, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.